Literature DB >> 20926426

Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.

Julien Laffaire1, Sibille Everhard, Ahmed Idbaih, Emmanuelle Crinière, Yannick Marie, Aurelien de Reyniès, Renaud Schiappa, Karima Mokhtari, Khê Hoang-Xuan, Marc Sanson, Jean-Yves Delattre, Joëlle Thillet, François Ducray.   

Abstract

Extensive genomic and gene expression studies have been performed in gliomas, but the epigenetic alterations that characterize different subtypes of gliomas remain largely unknown. Here, we analyzed the methylation patterns of 807 genes (1536 CpGs) in a series of 33 low-grade gliomas (LGGs), 36 glioblastomas (GBMs), 8 paired initial and recurrent gliomas, and 9 controls. This analysis was performed with Illumina's Golden Gate Bead methylation arrays and was correlated with clinical, histological, genomic, gene expression, and genotyping data, including IDH1 mutations. Unsupervised hierarchical clustering resulted in 2 groups of gliomas: a group corresponding to de novo GBMs and a group consisting of LGGs, recurrent anaplastic gliomas, and secondary GBMs. When compared with de novo GBMs and controls, this latter group was characterized by a very high frequency of IDH1 mutations and by a hypermethylated profile similar to the recently described glioma CpG island methylator phenotype. MGMT methylation was more frequent in this group. Among the LGG cluster, 1p19q codeleted LGG displayed a distinct methylation profile. A study of paired initial and recurrent gliomas demonstrated that methylation profiles were remarkably stable across glioma evolution, even during anaplastic transformation, suggesting that epigenetic alterations occur early during gliomagenesis. Using the Cancer Genome Atlas data set, we demonstrated that GBM samples that had an LGG-like hypermethylated profile had a high rate of IDH1 mutations and a better outcome. Finally, we identified several hypermethylated and downregulated genes that may be associated with LGG and GBM oncogenesis, LGG oncogenesis, 1p19q codeleted LGG oncogenesis, and GBM oncogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20926426      PMCID: PMC3018904          DOI: 10.1093/neuonc/noq110

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  64 in total

1.  Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas.

Authors:  Anke Waha; Stefanie Güntner; Tim Hui-Ming Huang; Pearlly S Yan; Bülent Arslan; Torsten Pietsch; Otmar D Wiestler; Andreas Waha
Journal:  Neoplasia       Date:  2005-03       Impact factor: 5.715

2.  A combination of molecular cytogenetic analyses reveals complex genetic alterations in conventional renal cell carcinoma.

Authors:  Jon C Strefford; Irina Stasevich; Tim M Lane; Yong-Jie Lu; Tim Oliver; Bryan D Young
Journal:  Cancer Genet Cytogenet       Date:  2005-05

3.  EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma.

Authors:  Miguel Alaminos; Verónica Dávalos; Santiago Ropero; Fernando Setién; Maria F Paz; Michel Herranz; Mario F Fraga; Jaume Mora; Nai-Kong V Cheung; William L Gerald; Manel Esteller
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

4.  High-throughput DNA methylation profiling using universal bead arrays.

Authors:  Marina Bibikova; Zhenwu Lin; Lixin Zhou; Eugene Chudin; Eliza Wickham Garcia; Bonnie Wu; Dennis Doucet; Neal J Thomas; Yunhua Wang; Ekkehard Vollmer; Torsten Goldmann; Carola Seifart; Wei Jiang; David L Barker; Mark S Chee; Joanna Floros; Jian-Bing Fan
Journal:  Genome Res       Date:  2006-01-31       Impact factor: 9.043

5.  TP53 promoter methylation in human gliomas.

Authors:  Vishwa Jeet Amatya; Ulrike Naumann; Michael Weller; Hiroko Ohgaki
Journal:  Acta Neuropathol       Date:  2005-07-16       Impact factor: 17.088

6.  Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer.

Authors:  Murali D Bashyam; Ryan Bair; Young H Kim; Pei Wang; Tina Hernandez-Boussard; Collins A Karikari; Robert Tibshirani; Anirban Maitra; Jonathan R Pollack
Journal:  Neoplasia       Date:  2005-06       Impact factor: 5.715

7.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

8.  Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

Authors:  Maria Möllemann; Marietta Wolter; Jörg Felsberg; V Peter Collins; Guido Reifenberger
Journal:  Int J Cancer       Date:  2005-01-20       Impact factor: 7.396

9.  Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation.

Authors:  J F Costello; M S Berger; H S Huang; W K Cavenee
Journal:  Cancer Res       Date:  1996-05-15       Impact factor: 12.701

10.  Antitumor activity of the novel human breast cancer growth inhibitor, mammary-derived growth inhibitor-related gene, MRG.

Authors:  Y E Shi; J Ni; G Xiao; Y E Liu; A Fuchs; G Yu; J Su; J M Cosgrove; L Xing; M Zhang; J Li; B B Aggarwal; A Meager; R Gentz
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

View more
  62 in total

1.  Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: association with tumor WHO grade and clinical outcome.

Authors:  Angela Di Vinci; Ida Casciano; Elena Marasco; Barbara Banelli; Gian Luigi Ravetti; Luana Borzì; Claudio Brigati; Alessandra Forlani; Alessandra Dorcaratto; Giorgio Allemanni; Gianluigi Zona; Renato Spaziante; Henning Gohlke; Giovanni Gardin; Domenico Franco Merlo; Vilma Mantovani; Massimo Romani
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-27       Impact factor: 4.553

Review 2.  Malignant transformation in pediatric spinal intramedullary tumors: case-based update.

Authors:  E Winograd; N Pencovich; M Yalon; D Soffer; L Beni-Adani; S Constantini
Journal:  Childs Nerv Syst       Date:  2012-07-10       Impact factor: 1.475

3.  Bayesian genome- and epigenome-wide association studies with gene level dependence.

Authors:  Eric F Lock; David B Dunson
Journal:  Biometrics       Date:  2017-01-12       Impact factor: 2.571

Review 4.  Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.

Authors:  Changcun Guo; Christopher J Pirozzi; Giselle Y Lopez; Hai Yan
Journal:  Curr Opin Neurol       Date:  2011-12       Impact factor: 5.710

Review 5.  The evolving molecular genetics of low-grade glioma.

Authors:  Sriram Venneti; Jason T Huse
Journal:  Adv Anat Pathol       Date:  2015-03       Impact factor: 3.875

6.  Identification of TET1 Partners That Control Its DNA-Demethylating Function.

Authors:  Pierre-François Cartron; Arulraj Nadaradjane; Fiona Lepape; Lisenn Lalier; Betty Gardie; François M Vallette
Journal:  Genes Cancer       Date:  2013-05

Review 7.  Metabolic modulation of epigenetics in gliomas.

Authors:  Sriram Venneti; Craig B Thompson
Journal:  Brain Pathol       Date:  2013-03       Impact factor: 6.508

Review 8.  New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.

Authors:  Michael Karsy; Jian Guan; Adam L Cohen; Randy L Jensen; Howard Colman
Journal:  Curr Neurol Neurosci Rep       Date:  2017-02       Impact factor: 5.081

9.  The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence.

Authors:  Wanyu L Lambiv; Irene Vassallo; Mauro Delorenzi; Tal Shay; Annie-Claire Diserens; Anjan Misra; Burt Feuerstein; Anastasia Murat; Eugenia Migliavacca; Marie-France Hamou; Davide Sciuscio; Raphael Burger; Eytan Domany; Roger Stupp; Monika E Hegi
Journal:  Neuro Oncol       Date:  2011-06-03       Impact factor: 12.300

Review 10.  IDH mutations in human glioma.

Authors:  Won Kim; Linda M Liau
Journal:  Neurosurg Clin N Am       Date:  2012-05-31       Impact factor: 2.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.